Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
Federal PolicyJune 5, 2026

FDA Launches Safety Review of Abortion Drug Mifepristone

The Food and Drug Administration has initiated a safety review of mifepristone, the abortion medication, according to an administration official. The retrospective analysis could lead to restrictions on the drug's use and distribution channels. Anti-abortion groups view this as a significant development that may result in tighter federal controls over medication abortion access. The timing and scope of the review have not been disclosed.

Why it mattersIf FDA restricts mifepristone distribution or availability, Medicaid managed care plans may face changes to pharmacy networks, prior authorization protocols, and access to medication abortion services covered under state Medicaid programs.

Maternal · Pharmacy · Managed Care

Read the full article at thehill.com →
Share this briefing

You might also like

← All stories

Get the daily briefing.